CN1723881A - Compounding medicine contg. coenzyme O30 for treating dermatosis, and its prepn. method - Google Patents
Compounding medicine contg. coenzyme O30 for treating dermatosis, and its prepn. method Download PDFInfo
- Publication number
- CN1723881A CN1723881A CNA2005100796500A CN200510079650A CN1723881A CN 1723881 A CN1723881 A CN 1723881A CN A2005100796500 A CNA2005100796500 A CN A2005100796500A CN 200510079650 A CN200510079650 A CN 200510079650A CN 1723881 A CN1723881 A CN 1723881A
- Authority
- CN
- China
- Prior art keywords
- treatment
- coenzyme
- pharmaceutical composition
- dermopathic
- contains coenzyme
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
A composition containing Co-Q10 for treating dermatopathy, especially for restoring the skin ulcer caused by fungus infection or other causes, is prepared from Co-Q10 (0.001-79 Wt %) and the additives chosen from emulsifier, liposoluble solvent, matrix, anti-oxidizing and water through homogenizing.
Description
Technical field
The present invention relates to a kind of dermopathic composite medicine of treatment of field of medicaments, particularly relate to a kind of composition and method of making the same for the treatment of tinea pedis.
Background technology
Coenzyme Q10 is the fat-soluble quinones that extensively exists in the human body.Its plays an important role in proton displacement and the electron transport in human body internal respiration chain, is the activator of Cellular respiration and cellular metabolism, also is important antioxidants and nonspecific immunity strengthening agent.
" Chinese pharmacopoeia began coenzyme Q10 is included since 2000, as the medicine of clinical use at home.Be applicable to the auxiliary treatment of following disease:
Cardiovascular disease is as viral myocarditis, chronic cardiac insufficiency;
Hepatitis is as viral hepatitis, subacute severe hepatitis, chronic active hepatitis;
The comprehensive control of cancer can alleviate the untoward reaction that radiotherapy, chemotherapy cause.
" the coenzyme Q10 dosage form of Chinese pharmacopoeia defined is: coenzyme Q10 sheet, coenzyme Q10 soft capsule, coenzyme Q 10 injection, coenzyme Q10 capsule.(see " 2005 editions 654 pages of Chinese pharmacopoeia)
Coenzyme Q10 is a kind of sophisticated medicine for oral administration, has not yet to see to be the report of coenzyme Q10 as topical drug.
Because the defective that above-mentioned coenzyme Q10 exists on using, the inventor is based on being engaged in this series products abundant for many years practical experience and Professional knowledge, and the utilization of cooperation scientific principle, actively studied innovation, in the hope of founding a kind of new dermopathic compositions of the treatment that contains coenzyme Q10, make it have more practicality.Through constantly research, test, and after studying sample and improvement repeatedly, create the present invention who has practical value finally.
Summary of the invention
The objective of the invention is to, a kind of compositions that contains coenzyme Q10 is provided, technical problem to be solved is to make its formation can be used for the treatment of dermopathic topical drug, thereby is suitable for practicality more.
Another object of the present invention is to, a kind of preparation of compositions method that contains coenzyme Q10 is provided, technical problem to be solved is it can be produced be suitable for the practical dermopathic topical drug of treatment.
The object of the invention to solve the technical problems realizes by the following technical solutions.The dermopathic pharmaceutical composition of the treatment that contains coenzyme Q10 according to the present invention's proposition, its weight percentage that contains coenzyme Q10 is 0.001%～79%, remaining is for making the usual component of medicinal unguentum, and wherein said usual component is wherein one or more of emulsifying agent, fat-soluble solvent, substrate, antioxidant and water.
The object of the invention to solve the technical problems also adopts following technical measures further to realize.
The aforesaid dermopathic pharmaceutical composition of treatment that contains coenzyme Q10, wherein said emulsifying agent are one of them or the combinations of two kinds of materials in the following material: emulsifying agent 343 (Emulsify343) and emulsified silicone oil (Silicone oil).
The aforesaid dermopathic pharmaceutical composition of treatment that contains coenzyme Q10, wherein said fat-soluble solvent are one of them or the combinations of two kinds of materials in the following material: polyvinylpyrrolidone (Polyvinylpyrrolidone K-30), glycerol (Glycerin).
The aforesaid dermopathic pharmaceutical composition of treatment that contains coenzyme Q10, wherein said substrate be propylene glycol (1,2-Propanediol).
The aforesaid dermopathic pharmaceutical composition of treatment that contains coenzyme Q10, wherein said antioxidant are tea tree oil (Tea tree oil);
The aforesaid dermopathic pharmaceutical composition of treatment that contains coenzyme Q10, the weight percentage of wherein said coenzyme Q10 is 0.001%～30%.
The aforesaid dermopathic pharmaceutical composition of treatment that contains coenzyme Q10, the weight percentage of wherein said coenzyme Q10 is 0.05%～9%.
The aforesaid dermopathic pharmaceutical composition of treatment that contains coenzyme Q10, the weight percentage of wherein said emulsifying agent is 0.01%～50%.
The aforesaid dermopathic pharmaceutical composition of treatment that contains coenzyme Q10, the weight percentage of wherein said emulsifying agent is 0.01%～28.5%.
The aforesaid dermopathic pharmaceutical composition of treatment that contains coenzyme Q10, the weight percentage of wherein said emulsifying agent is 0.3%～12.5%.
The aforesaid dermopathic pharmaceutical composition of treatment that contains coenzyme Q10, the weight percentage of wherein said fat-soluble solvent is 0.01%～50%.
The aforesaid dermopathic pharmaceutical composition of treatment that contains coenzyme Q10, the weight percentage of wherein said fat-soluble solvent is 0.01%～15%.
The aforesaid dermopathic pharmaceutical composition of treatment that contains coenzyme Q10, the weight percentage of wherein said substrate is 0.01%～30%.
The aforesaid dermopathic pharmaceutical composition of treatment that contains coenzyme Q10, the weight percentage of wherein said antioxidant is 0.01%～30%.
The aforesaid dermopathic pharmaceutical composition of treatment that contains coenzyme Q10, the weight percentage of wherein said antioxidant is 0.5%～9.5%.
Above-mentioned pharmaceutical composition is prepared to external preparation, and described preparation is a unguentum, and described specifically preparation is the emulsifying unguentum.
The object of the invention to solve the technical problems also realizes by the following technical solutions.The dermopathic preparation of compositions method of the treatment that contains coenzyme Q10 that proposes according to the present invention is: with carrying out homogeneity in coenzyme Q10 and solvent and/or fat-soluble solvent and/or emulsifying agent and/or substrate and/or antioxidant and/or water adding homogenizer or the other machines, promptly obtain the dermopathic compositions of treatment that contains coenzyme Q10 of the present invention after homogeneity is finished.
The dermopathic compositions of the treatment that contains coenzyme Q10 of proposition of the present invention also can be according to the conventional production method preparation of the medicine for external use of pharmaceutical field.
The aforesaid dermopathic compositions of treatment that contains coenzyme Q10, wherein said dermatosis is tinea pedis, the tinea manuum, eczema, psoriasis or fungus-caused skin ulceration.
The dermopathic compositions of the treatment that contains coenzyme Q10 of proposition of the present invention can be used in recovery owing to the skin ulceration that fungal infection and other reason cause, and impels its healing.The present invention proposes the dermopathic method for compositions of treatment that preparation contains coenzyme Q10 simultaneously.
Above-mentioned explanation only is the general introduction of technical solution of the present invention, for can clearer understanding technological means of the present invention, and can be implemented according to the content of description, and for above-mentioned and other purposes, feature and advantage of the present invention can be become apparent, below especially exemplified by preferred embodiment, be described in detail as follows.
The specific embodiment
Reach technological means and the effect that predetermined goal of the invention is taked for further setting forth the present invention, below in conjunction with preferred embodiment, to its concrete composition of the dermopathic compositions of the treatment that contains coenzyme Q10, preparation process, purposes and the effect thereof that foundation the present invention proposes, describe in detail as after.
Example 1
Coenzyme Q10: 0.001g
Emulsifying agent 343:28.5g
Polyvinylpyrrolidone: 15g
Propylene glycol: 30g
Tea tree oil: 9.5g
Water: 16.999g
Preparation method: according to above-mentioned each components contents, above-mentioned each component is added in the homogenizer, homogeneity obtained externally used paste of the present invention after 2 hours.
Example 2
Coenzyme Q10: 9g
Emulsifying agent 343:0.3g
Polyvinylpyrrolidone: 50g
Propylene glycol: 10g
Tea tree oil: 5g
Water: 25.7g
Preparation method: according to above-mentioned each components contents, above-mentioned each component is added in the homogenizer, homogeneity obtained externally used paste of the present invention after 2 hours.
Example 3
Coenzyme Q10: 79g
Emulsifying agent 343:0.01g
Polyvinylpyrrolidone: 0.01g
Propylene glycol: 10g
Tea tree oil: 5g
Water: 5.98g
Preparation method: according to above-mentioned each components contents, above-mentioned each component is added in the homogenizer, homogeneity obtained externally used paste of the present invention after 2 hours.
Example 4
Coenzyme Q10: 0.05g
Emulsifying agent 343:50g
Polyvinylpyrrolidone: 0.01g
Propylene glycol: 30g
Tea tree oil: 0.5g
Water: 19.44g
Preparation method: according to above-mentioned each components contents, above-mentioned each component is added in the homogenizer, homogeneity obtained externally used paste of the present invention after 2 hours.
Example 5
Coenzyme Q10: 30g
Emulsifying agent 343 12.5g
Polyvinylpyrrolidone: 10g
Glycerol: 5g
Propylene glycol: 20g
Tea tree oil: 4g
Water: 18.5g
Preparation method: according to above-mentioned each components contents, above-mentioned each component is added in the homogenizer, homogeneity obtained externally used paste of the present invention after 2 hours.
Example 6
Coenzyme Q10: 30g
Emulsified silicone oil: 25.5g
Polyvinylpyrrolidone: 5g
Glycerol: 10g
Propylene glycol: 15g
Tea tree oil: 0.5g
Water: 14g
Preparation method: according to above-mentioned each components contents, above-mentioned each component is added in the homogenizer, homogeneity obtained externally used paste of the present invention after 2 hours.
Example 7
Coenzyme Q10: 1g
Emulsified silicone oil: 5g
Emulsifying agent 343: 2g
Polyvinylpyrrolidone: 5g
Glycerol: 10g
Propylene glycol: 20g
Tea tree oil: 1g
Water: 56g
Preparation method: according to above-mentioned each components contents, above-mentioned each component is added in the homogenizer, homogeneity obtained externally used paste of the present invention after 2 hours.
The test example
Test method and consumption
The unguentum of the dermopathic compositions of treatment that contains coenzyme Q10 that the present invention is made is got and is applied to dermopathic site of pathological change in right amount, and massage makes unguentum infiltrate illing skin.Consumption is every day two to five times.After the disease symptom of site of pathological change disappears, continue to use 5 to 10 days, to consolidate result of use.
Above-mentioned dermatosis includes but not limited to: tinea pedis (beriberi), eczema, psoriasis (psoriasis), skin ulceration, skin Pruritus etc.
Test example 1
The week certain, man, 46 years old.Both feet are suffered from tinea pedis (beriberi), and symptom is that site of pathological change festers, decortication, Pruritus.The unguentum of the compositions of use-case 1 preparation, every day 2 times, transference cure after 23 days.Not recurrence after 6 months.
Test example 2
Lee, woman, 43 years old.Both feet are suffered from tinea pedis (beriberi), and symptom is that site of pathological change festers, decortication, Pruritus.The unguentum of the compositions of use-case 2 preparations, every day 3 times, transference cure after 26 days.Not recurrence after 3 months.
Test example 3
Ma, man, 53 years old.Both feet are suffered from tinea pedis (beriberi), and symptom is that site of pathological change festers, decortication, Pruritus.The unguentum of the compositions of use-case 3 preparations, every day 3 times, transference cure after 15 days.Not recurrence after 8 months.
Test example 4
Ma, woman, 23 years old.Skin eczema.Symptom is site of pathological change redness, Pruritus.The unguentum of the compositions of use-case 4 preparations, every day 5 times, transference cure after 15 days.Not recurrence after 8 months.
Test example 5
The Wang, man, 36 years old.Symptom is that skin peeling festers.The unguentum of the compositions of use-case 5 preparations, every day 3 times, transference cure after 15 days.
Test example 6
Grandson, man, 40 years old.The tinea manuum, symptom are that site of pathological change festers, decortication, Pruritus.The unguentum of the compositions of use-case 6 preparations, every day 4 times, transference cure after 15 days.
Experimental example 7
Zhao, woman, 30 years old.Psoriasis, symptom are site of pathological change decortication, Pruritus.The unguentum of the compositions of use-case 7 preparations, every day 5 times, transference cure after 30 days.
The above, it only is preferred embodiment of the present invention, be not that the present invention is done any pro forma restriction, though the present invention discloses as above with preferred embodiment, yet be not in order to limit the present invention, any those skilled in the art, in not breaking away from the technical solution of the present invention scope, when the method that can utilize above-mentioned announcement and technology contents are made a little change or be modified to the equivalent embodiment of equivalent variations, but every content that does not break away from technical solution of the present invention, according to technical spirit of the present invention to any simple modification that above embodiment did, equivalent variations and modification all still belong in the scope of technical solution of the present invention.
Claims (18)
1, a kind of dermopathic pharmaceutical composition of treatment that contains coenzyme Q10, its weight percentage that contains coenzyme Q10 is 0.001%～79%, remaining is for making the usual component of medicinal unguentum, and wherein said usual component is wherein one or more of emulsifying agent, fat-soluble solvent, substrate, antioxidant and water.
2, the dermopathic pharmaceutical composition of treatment that contains coenzyme Q10 according to claim 1 is characterized in that wherein said emulsifying agent is one of them or the two combination of emulsifying agent 343 and emulsified silicone oil.
3, the dermopathic pharmaceutical composition of treatment that contains coenzyme Q10 according to claim 1 is characterized in that wherein said fat-soluble solvent is polyvinylpyrrolidone and glycerol one of them or the two combination.
4, the dermopathic pharmaceutical composition of treatment that contains coenzyme Q10 according to claim 1 is characterized in that wherein said substrate is propylene glycol.
5, the dermopathic pharmaceutical composition of treatment that contains coenzyme Q10 according to claim 1 is characterized in that wherein said antioxidant is a tea tree oil.
6, according to the described dermopathic pharmaceutical composition of treatment that contains coenzyme Q10 of the arbitrary claim of claim 1 to 5, the weight percentage that it is characterized in that wherein said coenzyme Q10 is 0.001%～30%.
7, according to the described dermopathic pharmaceutical composition of treatment that contains coenzyme Q10 of the arbitrary claim of claim 1 to 5, the weight percentage that it is characterized in that wherein said coenzyme Q10 is 0.05%～9%.
8, according to the described dermopathic pharmaceutical composition of treatment that contains coenzyme Q10 of the arbitrary claim of claim 1 to 5, the weight percentage that it is characterized in that wherein said emulsifying agent is 0.01%～50%.
9, according to the described dermopathic pharmaceutical composition of treatment that contains coenzyme Q10 of the arbitrary claim of claim 1 to 5, the weight percentage that it is characterized in that wherein said emulsifying agent is 0.01%～28.5%.
10, according to the described dermopathic pharmaceutical composition of treatment that contains coenzyme Q10 of the arbitrary claim of claim 1 to 5, the weight percentage that it is characterized in that wherein said emulsifying agent is 0.3%～12.5%.
11, according to the described dermopathic pharmaceutical composition of treatment that contains coenzyme Q10 of the arbitrary claim of claim 1 to 5, the weight percentage that it is characterized in that wherein said fat-soluble solvent is 0.01%～50%.
12, the dermopathic pharmaceutical composition of treatment that contains coenzyme Q10 according to claim 8, the weight percentage that it is characterized in that wherein said fat-soluble solvent is 0.01%～15%.
13, according to the described dermopathic pharmaceutical composition of treatment that contains coenzyme Q10 of the arbitrary claim of claim 1 to 5, the weight percentage that it is characterized in that wherein said substrate is 0.01%～30%.
14, according to the described dermopathic pharmaceutical composition of treatment that contains coenzyme Q10 of the arbitrary claim of claim 1 to 5, the weight percentage that it is characterized in that wherein said antioxidant is 0.01%～30%.
15, according to the described dermopathic pharmaceutical composition of treatment that contains coenzyme Q10 of the arbitrary claim of claim 1 to 5, the weight percentage that it is characterized in that wherein said antioxidant is 0.5%～9.5%.
16,, it is characterized in that wherein said dermatosis is tinea pedis, the tinea manuum, eczema, psoriasis or fungus-caused skin ulceration according to the described dermopathic pharmaceutical composition of treatment that contains coenzyme Q10 of the arbitrary claim of claim 1 to 5.
17, a kind of dermopathic preparation of compositions method of treatment that contains coenzyme Q10, it may further comprise the steps: will carry out homogeneity in coenzyme Q10 and solvent and/or fat-soluble solvent and/or emulsifying agent and/or substrate and/or antioxidant and/or water adding homogenizer or the other machines; After finishing, homogeneity promptly obtains the dermopathic compositions of treatment that contains coenzyme Q10 of the present invention.
18, a kind of dermopathic preparation of compositions method of treatment that contains coenzyme Q10, it is according to the conventional production method preparation of the medicine for external use of pharmaceutical field.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2005100796500A CN1723881A (en) | 2005-06-23 | 2005-06-23 | Compounding medicine contg. coenzyme O30 for treating dermatosis, and its prepn. method |
| PCT/CN2006/001178 WO2006136081A1 (en) | 2005-06-23 | 2006-06-01 | A composition containing coenzyme q10 for treating dermatopathy, and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2005100796500A CN1723881A (en) | 2005-06-23 | 2005-06-23 | Compounding medicine contg. coenzyme O30 for treating dermatosis, and its prepn. method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1723881A true CN1723881A (en) | 2006-01-25 |
Family
ID=35923597
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2005100796500A Pending CN1723881A (en) | 2005-06-23 | 2005-06-23 | Compounding medicine contg. coenzyme O30 for treating dermatosis, and its prepn. method |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN1723881A (en) |
| WO (1) | WO2006136081A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102451180A (en) * | 2010-10-22 | 2012-05-16 | 马开龙 | External medicine for treating skin diseases and preparation method thereof |
| CN106265613A (en) * | 2016-09-05 | 2017-01-04 | 雄九（上海）医药技术股份有限公司 | Dermopathic compositions for the treatment of containing coenzyme Q10 and preparation method thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050070610A1 (en) * | 2000-05-09 | 2005-03-31 | Kenji Fujii | Dermal compositions containing coenzyme q as the active ingredient |
| JP4603192B2 (en) * | 2001-05-10 | 2010-12-22 | 株式会社カネカ | Hair scalp composition |
| SE0102380D0 (en) * | 2001-07-02 | 2001-07-02 | Macronova Ab | Cream for the treatment of age changes in the skin of man |
| TW200304373A (en) * | 2002-03-20 | 2003-10-01 | Kanegafuchi Chemical Ind | Percutaneous absorption promoters and compositions for treating athlete's foot |
-
2005
- 2005-06-23 CN CNA2005100796500A patent/CN1723881A/en active Pending
-
2006
- 2006-06-01 WO PCT/CN2006/001178 patent/WO2006136081A1/en active Application Filing
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102451180A (en) * | 2010-10-22 | 2012-05-16 | 马开龙 | External medicine for treating skin diseases and preparation method thereof |
| CN102451180B (en) * | 2010-10-22 | 2013-09-04 | 马开龙 | External medicine for treating skin diseases and preparation method thereof |
| CN106265613A (en) * | 2016-09-05 | 2017-01-04 | 雄九（上海）医药技术股份有限公司 | Dermopathic compositions for the treatment of containing coenzyme Q10 and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006136081A1 (en) | 2006-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1895239A (en) | Curcumin preparation and its making method | |
| CN1947701A (en) | Solid self-micro emulsion contg. jervic alcohol for antineoplastic medicine and its prepn. method | |
| CN1723881A (en) | Compounding medicine contg. coenzyme O30 for treating dermatosis, and its prepn. method | |
| CN1803185A (en) | Compound zedoary turmeric oil gelata and its preparing method | |
| CN1771937A (en) | Externally applied podophyllotoxin ointment and its prepn | |
| CN101049337A (en) | Medication for curing furuncle, sore, and carbuncle, and preparation method | |
| CN1748758A (en) | Dragon's blood gel preparation and its preparing method | |
| CN1270712C (en) | Felodipine controlled-release preparation | |
| CN1194956C (en) | Extraction and purification process of general rhubarb anthraquinone and its application in preparing kidney hypofuction-treating medicine | |
| CN1485037A (en) | Medication comprising nicotinic acid and tatin-like medicine | |
| CN101062024A (en) | Pronin medicinal composition and its preparing method | |
| CN1887292A (en) | Soft lentinan capsule and its prepn | |
| CN1634043A (en) | Zolmitriptan quick-release formulation | |
| CN1875949A (en) | Soft gastrodine capsule and preparation method thereof | |
| CN1911251A (en) | Traditional Chinese medicine enteric oral liquor using fresh earthworm extractive as active component, and its prepn. method | |
| CN1273115C (en) | Quick acting and heart resurrecting oral disintegrating tablet and its preparation process | |
| CN1555834A (en) | Medicinal composition containing salvia root effective component and ligusticum effecive component and its preparation | |
| CN1562044A (en) | Witamin D2 calcium levulinate freeze-dried emulsion and its preparing method | |
| CN1305473C (en) | Rubitecan containing formulation for injection | |
| CN1164273C (en) | Natural oral liquor for treatment of women's climacteric syndrome | |
| CN1152690C (en) | Composite Triamcinolone Acetonide medicine for treating germ-free inflammation | |
| CN1660071A (en) | Application of injection of quick dissolving solid in yew alkyl class in preparing medicine for anti transfer of tumor | |
| CN1695689A (en) | New type quick oral disintegration tablet of Subing and preparation method | |
| CN1634071A (en) | Gel agent for treating glaucoma and its preparing process | |
| CN1059338A (en) | The preparation of cantharidia liposoluble pharmaceutics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1087325 Country of ref document: HK |
|
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1087325 Country of ref document: HK |